Skip to main content
Glama

Compare Entities

compare_entities
Read-onlyIdempotent

"Compare X and Y" / "X vs Y" / "X versus Y" / "which is bigger / better / larger / more profitable" / "rank these companies" / "head to head" — side-by-side comparison of 2–5 companies or drugs in ONE parallel call. ALWAYS PREFER over sequential single-pack lookups when comparing entities. type="company" pulls LATEST 10-K revenue + net income + cash + long-term debt from SEC EDGAR/XBRL (off-calendar fiscal years handled correctly — AAPL Sep, NVDA Jan, etc.). type="drug" pulls FAERS adverse-event counts, FDA approval counts, active trial counts. Results sorted by primary metric so "largest" / "most" / "biggest" reads off the top of the response. Returns paired data + pipeworx:// citation URIs per entity. Replaces 8–15 sequential lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valuesYesFor company: 2–5 tickers/CIKs (e.g., ["AAPL","MSFT"]). For drug: 2–5 names (e.g., ["ozempic","mounjaro"]).

TDQS

A4.7/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

The description adds substantial behavioral details beyond annotations: for type='company' it pulls latest 10-K financials with correct off-calendar handling; for type='drug' it pulls FAERS, FDA approval, and trial counts. It also mentions sorting by primary metric and returning paired data with citation URIs. No contradiction with annotations (readOnlyHint, openWorldHint, etc.).

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is moderately long but well-structured. It front-loads trigger phrases to aid tool selection, then explains functionality and returns. Every sentence adds value, though a minor reduction in verbosity could improve conciseness.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Despite lacking an output schema, the description covers all critical aspects: input constraints (2-5 entities), behavior per type, sorting, and output format (paired data + citation URIs). This is comprehensive enough for an agent to use the tool correctly.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100%, but the description adds meaning: it explains that 'company' values should be tickers/CIKs and 'drug' values names, and clarifies what each entity type returns. It also gives examples like ['AAPL','MSFT'] and ['ozempic','mounjaro'], which helps the agent select correct inputs.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description starts with clear trigger phrases ('Compare X and Y', 'X vs Y', etc.) and explicitly states the tool performs 'side-by-side comparison of 2–5 companies or drugs'. It distinguishes this from sequential single-pack lookups, which are likely done by sibling tools like entity_profile.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description explicitly says 'ALWAYS PREFER over sequential single-pack lookups when comparing entities', providing strong guidance on when to use. It also gives example queries. However, it does not explicitly mention when not to use it (e.g., for more than 5 entities), but the context is clear enough.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.6/5.0
Disambiguation2/5

There are several near-duplicate clusters: ask_pipeworx, ask_pipeworx_beta (explicitly described as currently identical), ask_pipeworx_grounded, deep_research, and validate_claim all route to the same underlying data; the six Polymarket tools (bet_research, arbitrage, edges, edge_tracker, fill_risk, kalshi_spread) heavily overlap in purpose and are easy to confuse. Even detailed descriptions do not fully resolve which tool an agent should pick first.

Naming Consistency3/5

All names use snake_case and many follow a verb_noun pattern (search_filings, get_filing, list_issue_codes, resolve_entity), but there is a mix of verb-first names (ask_pipeworx, compare_entities, generate_llms_txt), noun-first names (recent_changes, entity_profile, pipeworx_trending), and brand-prefixed families (pipeworx_*, polymarket_*). The naming is readable but not a single predictable pattern.

Tool Count2/5

A server named 'Senate Lobbying' exposes 34 tools, but only three (search_filings, get_filing, list_issue_codes) relate to LDA lobbying data. The remaining 31 cover generic Pipeworx data lookup, prediction markets, memory, subscriptions, AI visibility, and npm package audits—an extreme overreach for the apparent scope and likely to confuse an agent expecting a focused lobbying toolkit.

Completeness2/5

For the lobbying domain implied by the server name, only search, get-one-filing, and issue-code enumeration exist; there is no aggregation/stats tool, no lobbyist/client entity resolution for LDA, no registrant or foreign-entity browsing, and no coverage of related concepts like lobbying firm hierarchies or spending trends. The generic Pipeworx tools fill a different domain, so the lobbying-specific surface has significant gaps.